Unexpected Adverse Events of Immune Checkpoint Inhibitors
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment standards and significantly enhanced patient prognoses. However, the utilization of these groundbreaking therapies has led to the observation and reporting of various types of adverse events, commonly known a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/8/1657 |
| _version_ | 1827729418041163776 |
|---|---|
| author | Walid Shalata Alexander Yakobson Aharon Y. Cohen Iris Goldstein Omar Abu Saleh Yulia Dudnik Keren Rouvinov |
| author_facet | Walid Shalata Alexander Yakobson Aharon Y. Cohen Iris Goldstein Omar Abu Saleh Yulia Dudnik Keren Rouvinov |
| author_sort | Walid Shalata |
| collection | DOAJ |
| description | The introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment standards and significantly enhanced patient prognoses. However, the utilization of these groundbreaking therapies has led to the observation and reporting of various types of adverse events, commonly known as immune-related adverse events (irAEs). In the following article, we present four patients who encountered uncommon toxicities induced by ICIs. The first patient was a 59-year-old female diagnosed with stage 4 lung adenocarcinoma. She received immunotherapy (pembrolizumab) together with chemotherapy and subsequently developed autonomic neuropathy (AN). The next two patients also received chemo-immunotherapy (pembrolizumab) and were both 63-year-old males with stage 4 lung adenocarcinoma. One of the two experienced palmoplantar keratoderma, while the other presented with Reiter’s syndrome (urethritis, conjunctivitis and arthritis). The 4th patient, an 80-year-old male with stage 4 squamous cell carcinoma of the lung, received chemo-immunotherapy (pembrolizumab) and developed myasthenia gravis. |
| first_indexed | 2024-03-10T23:47:33Z |
| format | Article |
| id | doaj.art-6a9e84347e5c4c5290b7a894d9b21764 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T23:47:33Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-6a9e84347e5c4c5290b7a894d9b217642023-11-19T01:53:40ZengMDPI AGLife2075-17292023-07-01138165710.3390/life13081657Unexpected Adverse Events of Immune Checkpoint InhibitorsWalid Shalata0Alexander Yakobson1Aharon Y. Cohen2Iris Goldstein3Omar Abu Saleh4Yulia Dudnik5Keren Rouvinov6The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben-Gurion University, Beer Sheva 84105, IsraelThe Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben-Gurion University, Beer Sheva 84105, IsraelThe Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben-Gurion University, Beer Sheva 84105, IsraelDepartment of Neurology, Faculty of Health Sciences, Soroka Medical Center, Ben-Gurion University, Beer Sheva 84105, IsraelDepartment of Dermatology and Venereology, The Emek Medical Centre, Afula 18341, IsraelThe Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben-Gurion University, Beer Sheva 84105, IsraelThe Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben-Gurion University, Beer Sheva 84105, IsraelThe introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment standards and significantly enhanced patient prognoses. However, the utilization of these groundbreaking therapies has led to the observation and reporting of various types of adverse events, commonly known as immune-related adverse events (irAEs). In the following article, we present four patients who encountered uncommon toxicities induced by ICIs. The first patient was a 59-year-old female diagnosed with stage 4 lung adenocarcinoma. She received immunotherapy (pembrolizumab) together with chemotherapy and subsequently developed autonomic neuropathy (AN). The next two patients also received chemo-immunotherapy (pembrolizumab) and were both 63-year-old males with stage 4 lung adenocarcinoma. One of the two experienced palmoplantar keratoderma, while the other presented with Reiter’s syndrome (urethritis, conjunctivitis and arthritis). The 4th patient, an 80-year-old male with stage 4 squamous cell carcinoma of the lung, received chemo-immunotherapy (pembrolizumab) and developed myasthenia gravis.https://www.mdpi.com/2075-1729/13/8/1657pembrolizumabpalmoplantar keratodermaReiter’s syndromemyasthenia gravisautonomic neuropathyimmune related adverse events |
| spellingShingle | Walid Shalata Alexander Yakobson Aharon Y. Cohen Iris Goldstein Omar Abu Saleh Yulia Dudnik Keren Rouvinov Unexpected Adverse Events of Immune Checkpoint Inhibitors Life pembrolizumab palmoplantar keratoderma Reiter’s syndrome myasthenia gravis autonomic neuropathy immune related adverse events |
| title | Unexpected Adverse Events of Immune Checkpoint Inhibitors |
| title_full | Unexpected Adverse Events of Immune Checkpoint Inhibitors |
| title_fullStr | Unexpected Adverse Events of Immune Checkpoint Inhibitors |
| title_full_unstemmed | Unexpected Adverse Events of Immune Checkpoint Inhibitors |
| title_short | Unexpected Adverse Events of Immune Checkpoint Inhibitors |
| title_sort | unexpected adverse events of immune checkpoint inhibitors |
| topic | pembrolizumab palmoplantar keratoderma Reiter’s syndrome myasthenia gravis autonomic neuropathy immune related adverse events |
| url | https://www.mdpi.com/2075-1729/13/8/1657 |
| work_keys_str_mv | AT walidshalata unexpectedadverseeventsofimmunecheckpointinhibitors AT alexanderyakobson unexpectedadverseeventsofimmunecheckpointinhibitors AT aharonycohen unexpectedadverseeventsofimmunecheckpointinhibitors AT irisgoldstein unexpectedadverseeventsofimmunecheckpointinhibitors AT omarabusaleh unexpectedadverseeventsofimmunecheckpointinhibitors AT yuliadudnik unexpectedadverseeventsofimmunecheckpointinhibitors AT kerenrouvinov unexpectedadverseeventsofimmunecheckpointinhibitors |